The trials indicated that all doses of tirzepatide resulted in greater weight loss and enhanced glycemic control in comparison to placebo
Comparison of breath- and blood-alcohol concentrations in a controlled drinking study
Dropout was higher in the 12 mg arm than in the 9 mg arm, reinforcing a pattern already visible in Phase 2: the marginal efficacy gain from pushing to 12 mg comes at real tolerability cost
These agents appear to modulate brain regions implicated in addiction, thereby reducing alcohol cravings and consumption, particularly among individuals with obesity [19, 20]
Once retatrutide is approved, you could switch
Some products are positioned more for diabetes, some for chronic weight management, and the dose-escalation plan matters a lot